Obesity and Glucose Metabolism

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 2268

Special Issue Editor


E-Mail Website
Guest Editor
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu 870-1192, Japan
Interests: food intake; energy expenditure; obesity; metabolism; glucose metabolism

Special Issue Information

Dear Colleagues,

Obesity is associated with significant morbidity and mortality and is increasing in prevalence worldwide. Obesity is also defined as an increased mass of adipose tissue, which confers a higher risk of diabetes. The pathophysiology that underlies obesity and glucose metabolism has not been fully elucidated, and effective therapeutic approaches are currently of general interest.

Multiple hormones and cytokines to obesity and glucose metabolism at several levels: hepatic, muscular, gastrointestinal tract and adipose tissue. In addition, several studies have revealed that the brain functions regulate eating behavior, nutrition and energy metabolism. The topics of “Obesity and Glucose Metabolism” that will be covered by this Special Issue include, but are not limited to, related metabolic factors, behavioral and pharmacological therapy that affect obesity and glucose metabolism. 

Both basic and clinical research focused on pathophysiological processes in obesity and glucose metabolism are welcome. This Special Issue is to publish high-quality original research articles and review articles in all aspects of metabolism relevant to the fields of obesity and glucose metabolism.

Dr. Takayuki Masaki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • obesity
  • diabetes
  • energy metabolism
  • glucose metabolism
  • pharmacological therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 258 KiB  
Article
Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients
by Takayuki Masaki, Yoshinori Ozeki, Yuichi Yoshida, Mitsuhiro Okamoto, Shotaro Miyamoto, Koro Gotoh and Hirotaka Shibata
Metabolites 2022, 12(2), 147; https://0-doi-org.brum.beds.ac.uk/10.3390/metabo12020147 - 04 Feb 2022
Cited by 3 | Viewed by 1780
Abstract
We evaluated time-course changes and the relationship between eating behavior and glycemic profile during the treatment of 34 obese type 2 diabetic patients with the glucagon-like peptide-1 receptor agonist (GLP1-RA) semaglutide. Changes in dietary habits were evaluated using the Japan Society for the [...] Read more.
We evaluated time-course changes and the relationship between eating behavior and glycemic profile during the treatment of 34 obese type 2 diabetic patients with the glucagon-like peptide-1 receptor agonist (GLP1-RA) semaglutide. Changes in dietary habits were evaluated using the Japan Society for the Study of Obesity questionnaire. Semaglutide improved body weight and hemoglobin A1C (HbA1c) 3 and 6 months after treatment. In addition, semaglutide led to marked improvements in the total scores for eating behavior items on the questionnaire. In particular, changes in the scores regarding the sensation of hunger, food preference, eating style, regularity of eating habits and emotional eating behavior were significantly improved during semaglutide treatment. By contrast, there were no significant changes in the scores for the recognition of weight and constitution and external eating behavior. Furthermore, changes in the scores regarding the sensation of hunger and food preference were correlated with changes in HbA1c after semaglutide treatment. Multivariable regression analyses showed that the change in the sensation of hunger was related to HbA1c during treatment. In conclusion, the GLP1-RA semaglutide regulates eating behavior, and, in particular, the sensation of hunger is closely related to the improvement in HbA1c by semaglutide in obese patients with type 2 diabetes. Full article
(This article belongs to the Special Issue Obesity and Glucose Metabolism)
Back to TopTop